Announcement on Change of Sponsor Representative for Continuous Supervision
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Change of Sponsor Representative for Continuous Supervision
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-change-of-sponsor-representative-for-continuous-supervision-163
Release
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Released at the 28the Chinese Society of Clinical Oncology (CSCO) Annual Meeting
- Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
- Announcement on Voluntary Disclosure of Obtaining FDA Approval for the Clinical Trial of ZG005 for Injection In Combination with ZGGS18 for Injection
- Announcement on Using Self-owned Funds to Pay Funds Required for Investment Projects Financed by Raised Funds and Replacing Them with an Equal Amount of Raised Funds
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of the Conduct of Key Clinical Trials for ZG006 for Injection and Completion of the Enrollment of the First Subject
- Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZGGS34 for Injection
- Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
- Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Reaching the Primary Efficacy Endpoint
- Announcement on Convening the Q3 2025 Performance Briefing
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals